Oragenics (OGEN) Enterprise Value (2010 - 2026)

Oragenics (OGEN) has 17 years of Enterprise Value data on file, last reported at -$6.1 million in Q1 2026.

• Quarterly Enterprise Value fell 78.31% year-over-year to -$6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.1 million (down 78.31% YoY) and the FY2025 annual result came in at -$8.4 million, down 871.25% from the prior year.
• Enterprise Value rose to -$6.1 million in Q1 2026, from -$8.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$864840.0 in Q4 2024 to a low of -$21.4 million in Q1 2022.
• A 5-year average of -$7.5 million and a median of -$6.1 million in 2026 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value jumped 79.17% — and 2025, when it tumbled 871.25%.
• Tracing OGEN's Enterprise Value over 5 years: stood at -$11.4 million in 2022, then soared by 69.51% to -$3.5 million in 2023, then soared by 75.17% to -$864840.0 in 2024, then plunged by 871.25% to -$8.4 million in 2025, then climbed by 27.38% to -$6.1 million in 2026.
• The last three Enterprise Value figures came in at -$6.1 million (Q1 2026), -$8.4 million (Q4 2025), and -$11.4 million (Q3 2025), per Business Quant data.